SECOND SUPPLEMENTAL INDENTURESecond Supplemental Indenture • November 8th, 2023 • Intercept Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
SECOND SUPPLEMENTAL INDENTURE (this “Second Supplemental Indenture”), dated as of November 8, 2023, between Intercept Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”), and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), a national banking association, as trustee (the “Trustee”), supplementing the indenture, dated as of August 17, 2021 (the indenture as so supplemented, “Indenture”), as supplemented by the First Supplemental Indenture, dated as of August 17, 2021 (the “First Supplemental Indenture”).
THIRD SUPPLEMENTAL INDENTUREThird Supplemental Indenture • November 8th, 2023 • Intercept Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIRD SUPPLEMENTAL INDENTURE (this “Third Supplemental Indenture”), dated as of November 8, 2023, between Intercept Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”), and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), a national banking association, as trustee (the “Trustee”), supplementing the Indenture for Senior Debt Securities, dated as of July 6, 2016 (the indenture as so supplemented, “Indenture”), as supplemented by the Second Supplemental Indenture, dated as of May 14, 2019 (the “Second Supplemental Indenture”).
